TriLink BioTechnologies

What TriLink BioTechnologies does

TriLink BioTechnologies is a San Diego-based Contract Development and Manufacturing Organization (CDMO) specializing in nucleic acid-based products and services, founded in 1996 and operating as a wholly-owned subsidiary of Maravai LifeSciences. The company serves the mRNA therapeutics, vaccine, gene editing, and broader nucleic acid drug development markets, with a customer base spanning academic researchers, biotechnology startups, and large pharmaceutical manufacturers. TriLink's commercial offering is anchored by its proprietary CleanCap cap analog technology, which enables co-transcriptional mRNA capping, supported by a catalog of IVT kits, CleanScribe RNA Polymerase, CleanAmp hot-start PCR reagents, and the newer ModTail modification kits, all protected by patents in multiple jurisdictions.

TriLink operates a dual business model. Its catalog reagents are sold through direct e-commerce and an international distributor network at price points ranging from approximately $65 to $11,000 per SKU, serving research-grade buyers. Its GMP-grade CDMO services are quote-based and encompass custom nucleic acid synthesis, mRNA manufacturing, and analytical support, delivered from a 118,000 sq ft San Diego facility and a newly opened 5,000 sq ft GMP enzyme plant in Jupiter, Florida. The company has produced 110+ GMP mRNA batches, and its chemistries are cited in 6,000+ scientific publications, with 500+ CleanCap constructs currently in preclinical or clinical development. TriLink is ISO 9001:2015 certified and operates under quality systems aligned with FDA GMP expectations.

The company is led by co-founder and CEO Richard Hogrefe and co-founder Terry Beck, with operational leadership provided by SVP of GMP Operations Ray Kaczmarek and VP of Commercial Sales Jeff Whitmore. TriLink has pursued ecosystem partnerships, including a 2025 collaboration with AI-driven mRNA designer Officinae Bio and upstream reagent provider Sartorius Polyplus, signaling intent to integrate across the mRNA development workflow. As a division of Maravai LifeSciences, TriLink's standalone financials are not separately disclosed.

Name

TriLink BioTechnologies

Legal name

TriLink BioTechnologies LLC

Website

https://trilinkbiotech.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

251–500 employees

Short description

TriLink BioTechnologies is a San Diego-based CDMO and catalog reagent supplier specializing in mRNA capping, IVT enzymes, and GMP nucleic acid manufacturing, serving vaccine, therapeutic, and gene-editing developers.

Ownership category

akta.pro rank

Product category

mRNA and Nucleic Acid CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

akta.pro secondary industries

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• MRNA manufacturing services
• Oligonucleotide synthesis
• CleanCap capping reagents
• GMP IVT enzymes
• Nucleic acid CDMO

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Research-Use Product Sales: Sale of IVT kits, enzymes, nucleotides, cap analogs, catalog RNAs, and oligonucleotides through e-commerce store and distributors for research applications.
2. CDMO Manufacturing Services: Contract development and manufacturing services for mRNA, gRNA, and oligonucleotides including GMP manufacturing for clinical trials and commercialization. Revenue generated through project-based quotes for discovery, preclinical, and GMP manufacturing.
3. Custom Synthesis Services: Custom nucleic acid chemistry services including modified nucleotides, oligonucleotides, and specialty constructs. Billed per project based on complexity and scale.
4. Analytical Services: In-house analytical testing and QC assay services for mRNA and oligo characterization, method development, and quality control for regulated applications.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

TriLink BioTechnologies manufactures custom oligonucleotides, modified nucleotides, and long RNA/mRNA products, and operates as a CDMO providing discovery, process development, GMP mRNA manufacturing, GMP enzyme manufacturing, analytical, and custom nucleic acid chemistry services for the diagnostic, therapeutic, and OEM markets. Its proprietary CleanCap capping, CleanScript IVT, CleanScribe polymerase, and ModTail technologies support the mRNA therapeutics and vaccine supply chain alongside a catalog of IVT kits, enzymes, nucleotides, cap analogs, catalog RNAs, and CRISPR guide RNA offerings.

Product overview

TriLink BioTechnologies is a contract development and manufacturing organization (CDMO) offering a comprehensive portfolio of nucleic acid tools and services for mRNA therapeutics and vaccines. The portfolio centers on CleanCap capping technology (including CleanCap IVT kits, CleanCap cap analogs, and CleanCap Reagents) and CleanScribe RNA Polymerase for reduced dsRNA formation. Key platform tools include the mRNABuilder and OligoBuilder design tools, plus a DNA Parts Collection. The company provides end-to-end CDMO services spanning discovery/preclinical RNA synthesis, GMP mRNA manufacturing, GMP enzyme manufacturing, and analytical services. Supporting products include modified nucleotides (N1-methylpseudouridine, 5-methoxyuridine, 5-methylcytidine), Catalog RNAs (reporter genes, genome editing, gene replacement, antigens), CleanAmp PCR products, Guide RNA manufacturing, and the ModTail technology for enhanced protein expression. The 118,000 sq ft San Diego facility and new 5,000 sq ft GMP enzyme facility in Jupiter, Florida support manufacturing from research through commercial scale.

Differentiator

Problem solved

Functional benefit

Products and services

• CleanCap IVT Kits High-yield in vitro transcription kits with CleanCap co-transcriptional capping technology producing optimal Cap1 structure with greater than 95% efficiency, available in CleanCap M6 and CleanCap AG (3' OMe) variants.
• CleanCap Cap Analogs (Reagents) Cap analog reagents for mRNA capping including CleanCap Reagent M6, CleanCap Reagent AG, CleanCap Reagent AG (3'OMe), and CleanCap Reagent AU for co-transcriptional capping.
• CleanScribe RNA Polymerase Engineered T7 RNA polymerase that reduces double-stranded RNA (dsRNA) formation by up to 85% compared to standard T7 RNA polymerases for mRNA manufacturing.
• T7 RNA Polymerase Wild-type T7 RNA polymerase enzyme for in vitro transcription applications.
• Engineered RNase Inhibitor RNase inhibitor for protecting RNA from degradation during IVT and downstream applications.
• Inorganic Pyrophosphatase (IPPase) Enzyme used in IVT reactions to enhance mRNA yield by hydrolyzing pyrophosphate byproduct.
• Ribonucleotides (rNTPs) Unmodified and modified ribonucleotides including rATP, rCTP, rGTP, UTP, N1-Methylpseudouridine-5'-triphosphate (N1Ψ), 5-methoxyuridine (5moU), and 5-methylcytidine (5mC) for mRNA synthesis.
• Catalog RNAs Premade CleanCap mRNAs and self-amplifying RNAs (saRNAs) including reporter genes, genome editing constructs, gene replacement sequences, and antigens for formulation and delivery optimization.
• Self-Amplifying RNA (saRNA) Self-amplifying RNA constructs that enable extended protein expression with smaller doses.
• CleanAmp Products Chemically-modified nucleotides (e.g., CleanAmp dUTP, CleanAmp 7-deaza-dGTP) designed to improve specificity, sensitivity, and robustness of PCR amplification without requiring specially designed DNA polymerases.
• mRNA ModTail Kit
• mRNA CDMO Services Contract development and manufacturing organization services for mRNA including discovery and preclinical RNA services, process development, GMP mRNA manufacturing, and commercial manufacturing services.
• GMP mRNA Manufacturing Phase-appropriate GMP manufacturing for clinical trials and commercialization in a 118,000 sq ft San Diego facility with multiple specialized manufacturing suites.
• GMP Enzyme Manufacturing
• Analytical Services Comprehensive analytical testing and QC assay capabilities for mRNA and oligo characterization including identity, characterization, impurity, and safety testing.
• Custom Nucleic Acid Chemistry Custom synthesis of complex modified nucleotides and amidites from discovery phase to multi-kilogram scale-up quantities.
• Guide RNA (gRNA) Manufacturing Custom gRNA synthesis services including HPLC gRNA, arrayed CRISPR screens, and GMP gRNA manufacturing.
• mRNABuilder Design Tool Online design tool for designing, checking, and ordering custom mRNA constructs.
• OligoBuilder Design Tool Online tool for designing and ordering custom oligonucleotides.
• mitoPrimers Specialized primers for mitochondrial DNA (mtDNA) analysis, quality control tested with NIST-certified SRM 2392.

Quantifiable outcome

• Up to 85% dsRNA reduction using CleanScribe RNA Polymerase vs standard T7 RNA polymerase
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Officinae BiocoreStrategic or Co-development Partner · 15 October 2025Joint webinar collaboration featuring experts from Officinae Bio, TriLink BioTechnologies, and Sartorius Polyplus on mRNA design and delivery topics. Collaboration focuses on advancements in mRNA design and delivery, combining AI, chemical modifications, and lipid-based reagents to improve mRNA effectiveness.
• Sartorius PolypluscoreStrategic or Co-development Partner · 15 October 2025Joint webinar collaboration on mRNA design and delivery. Sartorius Polyplus provides lipid-based transfection reagents while TriLink contributes mRNA synthesis expertise. Focuses on improving mRNA effectiveness and biodistribution for therapeutic applications.
• International DistributorsminorChannel Partner/ Reseller/ DistributorNetwork of authorized international distributors extending TriLink's global market reach for product sales. Distributors handle local sales and customer support for research-use products.
• SartoriusTechnology or IntegrationSartorius Polyplus is featured in joint educational content about mRNA design and delivery. Their lipid-based reagents complement TriLink's mRNA synthesis capabilities for improved therapeutic outcomes.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Aldevron: Aldevron (now part of Danaher) is a direct competitor in nucleic acid and protein CDMO services for therapeutic developers, including plasmid DNA, mRNA, and recombinant protein GMP manufacturing. Highly comparable as a CDMO serving the same biotech customer base with similar scale and capabilities.
• Integrated DNA Technologies (IDT): IDT (acquired by Danaher) manufactures custom oligonucleotides, synthetic nucleic acids, and CRISPR reagents, and operates a GMP manufacturing facility for therapeutic nucleic acids. Directly comparable as a nucleic acid CDMO with overlapping product lines and customer segments.
• New England Biolabs: NEB is a leading manufacturer of enzymes and reagents for nucleic acid research and manufacturing, including RNA polymerases and modified nucleotides. Comparable as a research-use reagent supplier and emerging GMP enzyme manufacturer serving the same research and therapeutic developer customer base.
• Bio-Techne: Bio-Techne operates the ProteinSimple, R&D Systems, and ExoDx brands, including GMP-grade protein and reagent manufacturing. Comparable as a life science tools and services provider with overlap in research-use and GMP-grade biological products for therapeutic developers.
• Avecia (Nitto Denko Avecia): Avecia, part of Nitto Denko, is a CDMO specializing in nucleic acid and oligonucleotide manufacturing for therapeutic applications. Direct peer in custom oligo and nucleic acid CDMO services with similar customer base in oligonucleotide-based therapeutics.

Broad incumbents

• Lonza: Lonza is a global CDMO offering cell, gene, and mRNA manufacturing services at commercial scale for large pharmaceutical customers. Comparable as a broader CDMO incumbent with overlapping capabilities in nucleic acid and biologics manufacturing, but operating at much larger scale and broader scope.
• Catalent: Catalent (now part of Novo Holdings) is a major global CDMO providing formulation, fill-finish, and biologics manufacturing services. Comparable as a broad CDMO incumbent serving biotech and pharma customers, though its nucleic acid capabilities are more limited than TriLink's specialized focus.
• WuXi STA: WuXi STA is a global CDMO with nucleic acid, oligonucleotide, and mRNA manufacturing capabilities. Comparable as a large-scale CDMO with overlapping nucleic acid offerings, primarily serving international customers at competitive pricing.

Emerging players

• Genevant Sciences: Genevant is a lipid nanoparticle (LNP) delivery technology company for nucleic acid therapeutics. Comparable as an emerging player in the nucleic acid delivery value chain adjacent to TriLink's mRNA synthesis offerings, often co-developing with similar therapeutic developer customers.
• CureVac: CureVac is a clinical-stage mRNA therapeutics company developing vaccines and protein replacement therapies, with internal GMP manufacturing capabilities. Comparable as an emerging mRNA player that both competes for and utilizes external CDMO services for portions of its pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/trilink-biotechnologies
• Xx.com/trilinkbiotech
• Facebookfacebook.com/trilink-biotechnologies-145192425506598

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TriLink BioTechnologies